NCT07074977 (CPUO) is a Phase 2 clinical trial of nemolizumab in Chronic Pruritus of Unknown Origin, sponsored by Galderma R&D.

Who is sponsoring NCT07074977?

NCT07074977 is sponsored by Galderma R&D.

What drugs are being tested in NCT07074977?

Interventions in NCT07074977: nemolizumab, Placebo.

What condition does NCT07074977 study?

NCT07074977 studies Chronic Pruritus of Unknown Origin.

Is NCT07074977 still recruiting?

NCT07074977 is currently recruiting now. Last updated 28 May 2026.

Last reviewed 2026-05-28 · How we verify

NCT07074977: CPUO

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

An Exploratory Proof of Concept Study to Assess the Pharmacokinetics/Pharmacodynamics (PK/PD) of Nemolizumab in Adult Participants With Chronic Pruritus of Unknown Origin (CPUO)

Recruiting now Phase 2 Last updated 28 May 2026

What this trial tests

Phase 2 trial testing nemolizumab in Chronic Pruritus of Unknown Origin in 50 participants. Currently enrolling.

Timeline

20 October 2025

Primary endpoint
1 September 2026

1 January 2027

Quick facts

Lead sponsor	Galderma R&D
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	50
Start date	20 October 2025
Primary completion	1 September 2026
Estimated completion	1 January 2027
Sites	26 locations across United States, Canada

Drugs / interventions tested

nemolizumab (NEMOLIZUMAB) — full drug profile →
Placebo

Conditions studied

Chronic Pruritus of Unknown Origin — all drugs for Chronic Pruritus of Unknown Origin →

Sponsor

Galderma R&D — full company profile →

Who can join

18 and older, any sex, with Chronic Pruritus of Unknown Origin. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Population Pharmacokinetics (PopPK) Model of the Elimination of nemolizumab During the 16-week Treatment Period Point
Time frame: From Baseline up to Week 16
Point Estimate of Population Total Clearance (Cl/F) of nemolizumab will be reported.
Population Pharmacokinetics (PopPK) Model of the Distribution of nemolizumab During the 16-week Treatment Period Point
Time frame: From Baseline up to Week 16
Point Estimate of Population Volume of Distribution (Vd/F) of nemolizumab will be reported.
Population Pharmacokinetics (PopPK) Model of the Absorption of nemolizumab During the 16-week Treatment Period Point
Time frame: From Baseline up to Week 16
Point Estimate of Absorption Rate Constant (Ka) of nemolizumab will be reported.
Pharmacokinetic (PK)/Pharmacodynamic (PD) Model of the Effect of nemolizumab Systemic Exposure on Pruritus during 16-week Treatment Period
Time frame: From Baseline up to Week 16
Point Estimate of population IC50 of nemolizumab, i.e. the drug concentration required to produce 50% of the maximal inhibition of Average Peak Pruritus, will be reported.

Sponsor's own description

The primary objective of this study is to assess the PK/PD relationship of nemolizumab in adult participants aged 18 years or above with chronic pruritus of unknown origin (CPUO) during a 16-week treatment period.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Pathogenesis and Therapeutics for Chronic Pruritus of Unknown Origin: A Systematic Review.
Akiska YM, Gandhi I, Adler R, Fayyad D, et al · · 2026 · cited 1× · PMID 41531005 · DOI 10.1111/ijd.70259

Verify or expand the search:

Other trials of nemolizumab

Trials testing the same drug.

NCT05214794 — An Open-label, Phase 2 Study to Assess the Efficacy and Safety of Nemolizumab in Subjects With Systemic Sclerosis · Phase 2 · completed

Other Galderma R&D trials

Trials by the same sponsor.

NCT07047690 — A Study of Nemolizumab for the Treatment of Adults With Systemic Sclerosis · Phase 2 · recruiting
NCT07344584 — A Prospective Pilot Study to Evaluate Safety and Effectiveness of GP0122 and GP0124 for Correction of Lines and Wrinkles · NA · not yet recruiting
NCT07186413 — A Study to Compare the Efficacy, Safety and Pharmacokinetics of Trifarotene 50 mcg/g Cream in Chinese Subjects With Acne · Phase 3 · recruiting
NCT07398989 — A Clinical Study to Assess Efficacy and Tolerability of a Topical Skincare Product on Adults With Mature, Crepey Skin · Phase 4 · completed
NCT06988618 — Real-world Experience on Using Nemolizumab in the Treatment of Moderate-to- Severe Prurigo Nodularis in Adults · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07074977 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Galderma R&D
Last refreshed: 28 May 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07074977.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing